The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Open accessAbstract
The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin's lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the antitumor activity and toxicity of single-agent everolimus in patients with relapsed/refractory aggressive NHL. Patients received everolimus 10 mg PO daily. Response was assessed after two and six cycles, and then every three cycles until progression. A total of 77 patients with a median age of 70 years were enrolled. Patients had received a median of three previous therapies and 32% had undergone previous transplant. The overall response rate (ORR) was 30% (95% confidence interval: 20-41%), with 20 patients achieving a partial remission and 3 a complete remission unconfirmed. The ORR in diffuse large B cell was 30% (14/47), 32% (6/19) in mantle cell and 38% (3/8) in follicular grade 3. The median duration of response was 5.7 months. Grade 3 or 4 anemia, neutropenia and thrombocytopenia occurred in 14, 18 and 38% of patients, respectively. Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
VÉZINA, C., KUDELSKI, A., & SEHGAL, S. N. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.721 · Cited by 1,687
Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1003 · Cited by 1,355
Self-citationBeyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233
SEHGAL, S. N., BAKER, H., & VÉZINA, C. (1975) · The Journal of Antibiotics · doi:10.7164/antibiotics.28.727 · Cited by 947
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147025 · Cited by 622
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Self-citationDissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
Al-Tourah, A. J., Gill, K. K., Chhanabhai, M., Hoskins, P. J., Klasa, R. J., Savage, K. J., Sehn, L. H., Shenkier, T. N., Gascoyne, R. D., & Connors, J. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0283 · Cited by 377
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Wiernik, P. H., Lossos, I. S., Tuscano, J. M., Justice, G., Vose, J. M., Cole, C. E., Lam, W., McBride, K., Wride, K., Pietronigro, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3429 · Cited by 371
Self-citationYee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
Johnston, P. B., Inwards, D. J., Colgan, J. P., Laplant, B. R., Kabat, B. F., Habermann, T. M., Micallef, I. N., Porrata, L. F., Ansell, S. M., Reeder, C. B., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21664 · Cited by 219
Self-citationAnsell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., et al. (2008) · Cancer · doi:10.1002/cncr.23580 · Cited by 203
Self-citationDutton, A., Reynolds, G. M., Dawson, C. W., Young, L. S., & Murray, P. G. (2005) · The Journal of Pathology · doi:10.1002/path.1725 · Cited by 176
Gupta, M., Ansell, S. M., Novak, A. J., Kumar, S., Kaufmann, S. H., & Witzig, T. E. (2009) · Blood · doi:10.1182/blood-2009-05-220889 · Cited by 162
Self-citationHaritunians, T., Mori, A., O’Kelly, J., Luong, Q. T., Giles, F. J., & Koeffler, H. P. (2006) · Leukemia · doi:10.1038/sj.leu.2404471 · Cited by 158
Ghobrial, I. M., Gertz, M. A., LaPlant, B. R., Camoriano, J. K., Hayman, S. R., Lacy, M. Q., Chuma, S., Harris, B. N., Leduc, R., Rourke, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0994 · Cited by 135
Self-citationWanner, K., Hipp, S., Oelsner, M., Ringshausen, I., Bogner, C., Peschel, C., & Decker, T. W. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06210.x · Cited by 125
Armand, P. A., Gannamaneni, S., Kim, H. T., Cutler, C. S., Ho, V. T., Koreth, J., Alyea, E. P., LaCasce, A. S., Jacobsen, E. D., Fisher, D. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7279 · Cited by 114
Self-citationRamakrishnan, V. G., Timm, M., Haug, J., Kimlinger, T. K., Wellik, L. E., Witzig, T. E., Rajkumar, S. V., Adjei, A. A., & Kumar, S. K. (2009) · Oncogene · doi:10.1038/onc.2009.403 · Cited by 99
Self-citationWitzig, T. E., & Kaufmann, S. H. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0038-1 · Cited by 74
Self-citationWlodarski, P. K., Kasprzycka, M., Liu, X., Marzec, M., Robertson, E. S., Słupianek, A., & Wasik, M. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4180 · Cited by 74
Cited by
The mTOR Signalling Pathway in Human Cancer
Pópulo, H., Lopes, J. M., & Soares, P. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021886 · Cited by 830
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Schultze, S. M., Hemmings, B. A., Niessen, M., & Tschopp, O. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002109 · Cited by 540
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Diffuse large B-cell lymphoma—treatment approaches in the molecular era
Roschewski, M., Staudt, L. M., & Wilson, W. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.197 · Cited by 411
Metadata
- Authors
- Witzig, T. E., Reeder, C. B., LaPlant, B. R., Gupta, M., Johnston, P. B., Micallef, I. N., Porrata, L. F., Ansell, S. M., Colgan, J. P., Jacobsen, E. D., Ghobrial, I. M., & Habermann, T. M.
- Venue
- Leukemia
- Published
- 2010-12-07
- Volume
- 25
- Issue
- 2
- Pages
- 341-347
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2019874087
- Cited by
- 297
- References
- 31
- FWCI
- 18.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.